Skip to main content

Danaparoid Disease Interactions

There are 7 disease interactions with danaparoid.

Major

Anticoagulants (applies to danaparoid) hemophilia

Major Potential Hazard, High plausibility. Applicable conditions: Coagulation Defect

Anticoagulants should be given with extreme caution to patients with hemophilia or other congenital or acquired bleeding tendencies. The risk of hemorrhage may be increased in these patients.

References

  1. (2002) "Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer
  2. (2001) "Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company
  3. Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G (1986) "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis, 16 Suppl 2, p. 11-8
  4. (2001) "Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn
  5. (2001) "Product Information. Orgaran (danaparoid)." Organon
View all 5 references
Major

Anticoagulants (applies to danaparoid) liver disease

Major Potential Hazard, Low plausibility.

Anticoagulants should be given with extreme caution to patients at increased risk for hemorrhage, including patients who have severe liver disease with impaired hemostasis.

References

  1. (2002) "Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer
  2. (2001) "Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company
  3. Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G (1986) "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis, 16 Suppl 2, p. 11-8
  4. (2001) "Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn
  5. (2001) "Product Information. Orgaran (danaparoid)." Organon
View all 5 references
Major

Anticoagulants (applies to danaparoid) peptic ulcer disease

Major Potential Hazard, High plausibility. Applicable conditions: Bleeding

Anticoagulants are contraindicated in patients with active major bleeding or those patients at risk for hemorrhage. Hemorrhage due to heparin derivatives may be treated with protamine sulfate 1%. However, protamine sulfate may not completely neutralize the anti- Factor Xa activity.

References

  1. Oates JA, Wood AJJ (1991) "Heparin." N Engl J Med, 324, p. 1565-74
  2. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ (1991) "Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin." Blood, 78, p. 2337-43
  3. Walker AM, Jick H (1980) "Predictors of bleeding during heparin therapy." JAMA, 244, p. 1209-12
  4. Breddin HK (1989) "Low molecular weight heparins and bleeding." Semin Thromb Hemost, 15, p. 401-4
  5. (2002) "Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer
  6. (2001) "Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company
  7. Hirsh J, Fuster V (1994) "Guide to anticoagulant therapy. 1. Heparin." Circulation, 89, p. 1449-68
  8. Sugiyama T, Itoh M, Ohtawa M, Natsuga T (1992) "Study on neutralization of low molecular weight heparin (LHG) by protamine sulfate and its neutralization characteristics." Thromb Res, 68, p. 119-29
  9. (2001) "Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn
  10. (2001) "Product Information. Orgaran (danaparoid)." Organon
View all 10 references
Major

Anticoagulants (applies to danaparoid) retinopathy

Major Potential Hazard, Moderate plausibility. Applicable conditions: Diabetic Retinopathy, Hypertensive Retinopathy

The use of anticoagulants may increase the risk of bleeding in patients with hypertensive or diabetic retinopathy. Therapy with anticoagulants should be administered with extreme caution in such patients.

References

  1. (2002) "Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer
  2. (2001) "Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn
Major

Anticoagulants (applies to danaparoid) subacute bacterial endocarditis

Major Potential Hazard, High plausibility. Applicable conditions: Infectious Endocarditis

Anticoagulants should be given with extreme caution to patients with subacute bacterial endocarditis. The risk of hemorrhage may be increased in these patients.

References

  1. (2002) "Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer
  2. (2001) "Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company
  3. Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G (1986) "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis, 16 Suppl 2, p. 11-8
  4. (2001) "Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn
  5. (2001) "Product Information. Orgaran (danaparoid)." Organon
View all 5 references
Moderate

Anticoagulants (applies to danaparoid) hypertension

Moderate Potential Hazard, Moderate plausibility.

Anticoagulants should be used with extreme caution in patients at increased risk for hemorrhage, including those patients with severe hypertension.

References

  1. (2002) "Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer
  2. (2001) "Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company
  3. (2001) "Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn
  4. (2001) "Product Information. Orgaran (danaparoid)." Organon
View all 4 references
Moderate

Anticoagulants (applies to danaparoid) kidney disease

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

Anticoagulants should be given with extreme caution to patients with severe kidney dysfunction. Altered coagulation may increase the risk of bleeding in these patients. If an anticoagulant is administered, these patients should be monitored closely for signs of bleeding.

References

  1. (2002) "Product Information. Lovenox (enoxaparin)." Rhone Poulenc Rorer
  2. (2001) "Product Information. Heparin Sodium (heparin)." Lilly, Eli and Company
  3. Bergqvist D, Burmark US, Frisell J, Hallbook T, Lindblad B, Risberg B, Torngren S, Wallin G (1986) "Prospective double-blind comparison between Fragmin and conventional low-dose heparin: thromboprophylactic effect and bleeding complications." Haemostasis, 16 Suppl 2, p. 11-8
  4. (2001) "Product Information. Fragmin (dalteparin)." Pharmacia and Upjohn
  5. (2001) "Product Information. Orgaran (danaparoid)." Organon
View all 5 references

Danaparoid drug interactions

There are 172 drug interactions with danaparoid.

Danaparoid alcohol/food interactions

There is 1 alcohol/food interaction with danaparoid.

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer